Table 6.

In Vivo PK Profiles of Compounds 44 and 45 in Rats^a

		44	45
i.v. (10 mg/kg)	bt1/2 (h)	3.5 ± 0.71	4.1 ± 0.43
	cCmax (ng/mL)	2861 ± 426	2090 ± 265
	dAUC0-t (ng·h/mL)	6763 ± 590	7033 ± 2161
	eCL (L/h/kg)	1.48 ± 0.13	1.48 ± 0.38
p.o. (20 mg/kg)	t1/2 (h)	2.4 ± 0.55	2.8 ± 0.27
	Cmax (ng/mL)	575.1 ± 179	605.5 ± 182
	AUC0-t (ng·h/mL)	5171 ± 3447	4966 ± 1772
	fF (%)	38.2	35.3

^aCompounds were formulated in 10%DMSO/60%PEG400/30% Saline and administrated intravenously (i.v.) or per os (p.o.).

^bt_1/2, half-life.

^cC_max, maximum plasma concentration achieved.

^dAUC_0‑t, total exposure following a single dose.

^eCL, total clearance.

^fF, oral bioavailability.